Organogenesis Holdings Inc logo

ORGO - Organogenesis Holdings Inc Share Price

$3.9 -0.2  -3.9%

Last Trade - 4:45pm

Sector
Healthcare
Size
Small Cap
Market Cap £331.4m
Enterprise Value £389.4m
Revenue £208.8m
Position in Universe 3083rd / 6396
Bullish
Bearish
Unlock ORGO Revenue
Momentum
Relative Strength (%)
1m -8.20%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -51.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 193.4 261 275.1 288.3
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Organogenesis Holdings Inc revenues increased 7% to $130.7M. Net loss decreased 15% to $21.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Loss on the extinguishment of debt decrease from $1.9M (expense) to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$0.28 to -$0.21.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ORGO Revenue Unlock ORGO Revenue

Net Income

ORGO Net Income Unlock ORGO Revenue

Normalised EPS

ORGO Normalised EPS Unlock ORGO Revenue

PE Ratio Range

ORGO PE Ratio Range Unlock ORGO Revenue

Dividend Yield Range

ORGO Dividend Yield Range Unlock ORGO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ORGO EPS Forecasts Unlock ORGO Revenue
Profile Summary

Organogenesis Holdings Inc., formerly Avista Healthcare Public Acquisition Corp, is a regenerative medicine company. The Company focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. It also provides integrated healing solutions that substantially improve medical outcomes. The Company’s advanced wound care and surgical & sports medicine products include PuraPly, Antimicrobial (PuraPlyAM), PuraPly, Affinity, NuShield, Apligraf and Dermagraft. The Company is offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. The Company’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated December 10, 2018
Public Since December 2, 2016
No. of Shareholders: 84
No. of Employees: 835
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 105,417,168
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ORGO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ORGO
Upcoming Events for ORGO
Monday 21st September, 2020
Organogenesis Holdings Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual)
Frequently Asked Questions for Organogenesis Holdings Inc
What is the Organogenesis Holdings Inc share price?

As of 4:45pm, shares in Organogenesis Holdings Inc are trading at $3.9, giving the company a market capitalisation of £331.4m. This share price information is delayed by 15 minutes.

How has the Organogenesis Holdings Inc share price performed this year?

Shares in Organogenesis Holdings Inc are currently trading at $3.9 and the price has moved by -30.6% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Organogenesis Holdings Inc price has moved by -38.14% over the past year.

What are the analyst and broker recommendations for Organogenesis Holdings Inc?

Of the analysts with advisory recommendations for Organogenesis Holdings Inc, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Organogenesis Holdings Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Organogenesis Holdings Inc next release its financial results?

Organogenesis Holdings Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Organogenesis Holdings Inc dividend yield?

Organogenesis Holdings Inc does not currently pay a dividend.

Does Organogenesis Holdings Inc pay a dividend?

Organogenesis Holdings Inc does not currently pay a dividend.

When does Organogenesis Holdings Inc next pay dividends?

Organogenesis Holdings Inc does not currently pay a dividend.

How do I buy Organogenesis Holdings Inc shares?

To buy shares in Organogenesis Holdings Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Organogenesis Holdings Inc?

Shares in Organogenesis Holdings Inc are currently trading at $3.9, giving the company a market capitalisation of £331.4m.

Where are Organogenesis Holdings Inc shares listed? Where are Organogenesis Holdings Inc shares listed?

Here are the trading details for Organogenesis Holdings Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ORGO
What kind of share is Organogenesis Holdings Inc?

Based on an overall assessment of its quality, value and momentum, Organogenesis Holdings Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Organogenesis Holdings Inc share price forecast 2020?

Shares in Organogenesis Holdings Inc are currently priced at $3.9. At that level they are trading at 0.116% discount to the analyst consensus target price of 0.00.

Analysts covering Organogenesis Holdings Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.388 for the next financial year.

How can I tell whether the Organogenesis Holdings Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Organogenesis Holdings Inc. Over the past six months, the relative strength of its shares against the market has been -10.7%. At the current price of $3.9, shares in Organogenesis Holdings Inc are trading at 0.42% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Organogenesis Holdings Inc PE Ratio?

We were not able to find PE ratio data for Organogenesis Holdings Inc.

Who are the key directors of Organogenesis Holdings Inc?

Organogenesis Holdings Inc's management team is headed by:

Gary Gillheeney - PRE
Patrick Bilbo - COO
Lori Freedman - VPR
Brian Grow - OTH
Antonio Montecalvo - VPR
Alan Ades - IND
Maurice Ades - DRC
Albert Erani - IND
Glenn Nussdorf - DRC
Arthur Leibowitz - IND
Henry Hagopian - CFO
Who are the major shareholders of Organogenesis Holdings Inc?

Here are the top five shareholders of Organogenesis Holdings Inc based on the size of their shareholding:

Ades (Alan A) Individual Investor
Percentage owned: 42.19% (44.5m shares)
Avista Capital Holdings, LP Private Equity
Percentage owned: 23.69% (25.0m shares)
Nussdorf (Glenn H) Individual Investor
Percentage owned: 14.17% (14.9m shares)
Erani (Dennis) Individual Investor
Percentage owned: 4.07% (4.29m shares)
Erani (Albert) Individual Investor
Percentage owned: 3.48% (3.67m shares)
Similar to ORGO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.